Literature DB >> 10430212

Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group.

J L Jones1, D L Hanson, M S Dworkin, J W Ward, H W Jaffe.   

Abstract

We examined incidence trends in seven HIV-associated cancers (Kaposi's sarcoma [KS], invasive cervical cancer, immunoblastic lymphoma, primary brain lymphoma [PBL], Burkitt's lymphoma, other non-Hodgkin's lymphomas, and Hodgkin's lymphoma) and the effects of antiretroviral therapy on these trends. Data were abstracted from medical records in 89 hospitals and clinics in nine U.S. cities from January 1994 through June 1997. The stratified Cochran-Mantel-Haenszel statistic was used to test for trend. There were 19,684 HIV-infected persons representing 26,638 years of follow-up. Decreases in incidence per 1000 person-years were observed for KS (January through June 1994, 49.9; January through June 1997, 25.7; p = .001) and PBL (January through June 1994, 8.0; January through June 1997, 2.3; p = .01), especially during time on antiretroviral therapy, but changes in the incidence of other cancers were not significant. During the study, prescription of combination antiretroviral therapy increased from 16% to 57%. The incidences of KS and PBL are decreasing. Although for KS the decline occurred in both treated and untreated groups (difference in rate of decline not significant, p = .08), it was sharper in the treated group; additionally, KS declined faster in the era after highly active antiretroviral agents were introduced. Thus, these decreases may be due in part to the effect of antiretroviral therapy slowing the progression of HIV disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430212

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  12 in total

Review 1.  Clinical dilemmas in palliative care for HIV infection.

Authors:  S C Matheny
Journal:  J R Soc Med       Date:  2001-09       Impact factor: 5.344

2.  Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells.

Authors:  Sofia Corte-Real; Chris Collins; Frederico Aires da Silva; J Pedro Simas; Carlos F Barbas; Yuan Chang; Patrick Moore; Joao Goncalves
Journal:  Blood       Date:  2005-08-09       Impact factor: 22.113

3.  Secular trends in opportunistic infections, cancers and mortality in patients with AIDS during the era of modern combination antiretroviral therapy.

Authors:  E Sezgin; M L Van Natta; J E Thorne; M A Puhan; D A Jabs
Journal:  HIV Med       Date:  2018-03-24       Impact factor: 3.180

Review 4.  Metabolic reprogramming: a hallmark of viral oncogenesis.

Authors:  P Lévy; B Bartosch
Journal:  Oncogene       Date:  2015-12-21       Impact factor: 9.867

Review 5.  Management of AIDS-related non-Hodgkin's lymphomas.

Authors:  M J Kersten; R H Van Oers
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy.

Authors:  Moraima Guadalupe; Brad H Pollock; Steven Westbrook; Spencer Redding; Delia Bullock; Gregory Anstead; Brian K Agan; Vincent C Marconi; Sharon Barbieri; Vidya Sankar; Jennifer Rebeles; Yvette Flahive; John Schoolfield; Linding Wang; Xiufen Lei; Dorothy Dow; Chih-Ko Yeh; Howard Dang; Anthony J Infante; Shou-Jiang Gao
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

7.  Diagnosis and Treatment of Kaposi's Sarcoma.

Authors:  Muhammad Wasif Saif
Journal:  Resid Staff Physician       Date:  2001-11

Review 8.  Gynecologic issues in the HIV-infected woman.

Authors:  Helen E Cejtin
Journal:  Infect Dis Clin North Am       Date:  2008-12       Impact factor: 5.982

Review 9.  Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases.

Authors:  Dharam V Ablashi; Louise G Chatlynne; James E Whitman; Ethel Cesarman
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

10.  LANA-1, Bcl-2, Mcl-1 and HIF-1alpha protein expression in HIV-associated Kaposi sarcoma.

Authors:  E Long; M Ilie; V Hofman; K Havet; E Selva; C Butori; J P Lacour; A M Nelson; G Cathomas; P Hofman
Journal:  Virchows Arch       Date:  2009-05-30       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.